|
1
|
Adamo V, Antonuzzo L, Danova M, De
Laurentiis M, Marchetti P, Pinto C and Rosti G: Supportive
therapies in the prevention of chemotherapy-induced febrile
neutropenia and appropriate use of granulocyte colony-stimulating
factors: A Delphi consensus statement. Support Care Cancer.
30:9877–9888. 2022.PubMed/NCBI
|
|
2
|
Aapro M, Bohlius J, Cameron DA, Dal Lago
L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC,
Walewski J, et al: 2010 update of EORTC guidelines for the use of
granulocyte-colony-stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphoproliferative disorders and solid tumours. Eur J Cancer.
47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klastersky J, de Naurois J, Rolston K,
Rapoport B, Maschmeyer G, Aapro M and Herrstedt J; ESMO Guidelines
Committee, : Management of febrile neutropaenia: ESMO clinical
practice guidelines. Ann Oncol. 27 (Suppl 5):v111–v118. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith TJ, Bohlke K, Lyman GH, Carson KR,
Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB,
Perkins CL, et al: Recommendations for the use of WBC growth
factors: American society of clinical oncology clinical practice
guideline update. J Clin Oncol. 33:3199–3212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Igor Kiss: Blue Book of the Czech Oncology
Society. Recommendation concerning the treatment of haematologic
toxicities. 31st Edition. Masarykuv onkologicky ustav, Brno: Czech
Republic; pp. 277–280. 2025, https://www.linkos.cz/files/modra-kniha/25/973.pdfMarch
1–2025(In Czech).
|
|
6
|
Aapro M, Boccia R, Leonard R, Camps C,
Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, et al:
Refining the role of pegfilgrastim (a long-acting G-CSF) for
prevention of chemotherapy-induced febrile neutropenia: Consensus
guidance recommendations. Support Care Cancer. 25:3295–3304.
2017.PubMed/NCBI
|
|
7
|
Aapro M, Lyman GH, Bokemeyer C, Rapoport
BL, Mathieson N, Koptelova N, Cornes P, Anderson R, Gascón P and
Kuderer NM: Supportive care in patients with cancer during the
COVID-19 pandemic. ESMO Open. 6:1000382021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Griffiths EA, Alwan LM, Bachiashvili K,
Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ,
et al: Considerations for Use of Hematopoietic Growth Factors in
Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr
Canc Netw. 19:18–21. 2020. View Article : Google Scholar
|
|
9
|
von Minckwitz G, Schwenkglenks M, Skacel
T, Lyman GH, Pousa AL, Bacon P, Easton V and Aapro MS: Febrile
neutropenia and related complications in breast cancer patients
receiving pegfilgrastim primary prophylaxis versus current practice
neutropaenia management: results from an integrated analysis. Eur J
Cancer. 45:608–617. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aapro M, Schwenkglenks M, Lyman GH, Lopez
Pousa A, Lawrinson S, Skacel T, Bacon P and von Minckwitz G:
Pegfilgrastim primary prophylaxis vs. current practice neutropenia
management in elderly breast cancer patients receiving
chemotherapy. Crit Rev Oncol Hematol. 74:203–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurbacher CM, Fietz T, Trarbach T, Salat
C, Rezai M, Lorenz A and Niemeier B: 1457P - Prophylaxis of
chemotherapy-induced neutropenia with lipegfilgrastim in patients
with breast cancer: results from an interim analysis of the
non-interventional study NADIR. Annals of Oncology. 27:vi5052016.
View Article : Google Scholar
|
|
12
|
Steger G, Pichler P, Airoldi M, Mazza P,
Fontaine C, Timmer Bonte J, Walewski JA, Katolicka J, Mikulova M
and Gasparic M: Use of lipegfilgrastim for the prophylaxis of
chemotherapy-induced neutropenia: Pan-European non-interventional
study. Ann Oncol. 29 (Suppl 8):VIII607–VII608. 2018. View Article : Google Scholar
|
|
13
|
Bondarenko I, Gladkov OA, Elsaesser R,
Buchner A and Bias P: Efficacy and safety of lipegfilgrastim versus
pegfilgrastim: A randomized, multicenter, active-control phase 3
trial in patients with breast cancer receiving
doxorubicin/docetaxel chemotherapy. BMC Cancer. 13:386–398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gladkov OA, Buchner A, Bias P, Müller U
and Elsässer R: Chemotherapy-associated treatment burden in breast
cancer patients receiving lipegfilgrastim or pegfilgrastim:
secondary efficacy data from a phase III study. Support Care
Cancer. 24:395–400. 2016.PubMed/NCBI
|
|
15
|
Link H, Illerhaus G, Martens UM, Salar A,
Depenbusch R, Köhler A, Engelhardt M, Mahlmann S, Zaiss M,
Lammerich A, et al: Efficacy and safety of lipegfilgrastim versus
pegfilgrastim in elderly patients with aggressive B cell
non-Hodgkin lymphoma (B-NHL): Results of the randomized,
open-label, non-inferiority AVOID neutropenia study. Support Care
Cancer. 29:2519–2527. 2021.PubMed/NCBI
|
|
16
|
Lyman GH, Dale DC, Wolff DA, Culakova E,
Poniewierski MS, Kuderer NM and Crawford J: Acute myeloid leukemia
or myelodysplastic syndrome in randomized controlled clinical
trials of cancer chemotherapy with granulocyte colony-stimulating
factor: A systematic review. J Clin Oncol. 28:2914–2924. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hershman D, Neugut AI, Jacobson JS, Wang
J, Tsai WY, McBride R, Bennett CL and Grann VR: Acute myeloid
leukemia or myelodysplastic syndrome following use of granulocyte
colony-stimulating factors during breast cancer adjuvant
chemotherapy. J Natl Cancer Inst. 99:196–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calip GS, Malmgren JA, Lee WJ, Schwartz SM
and Kaplan HG: Myelodysplastic syndrome and acute myeloid leukemia
following adjuvant chemotherapy with and without granulocyte
colony-stimulating factors for breast cancer. Breast Cancer Res
Treat. 154:133–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jabagi MJ, Vey N, Goncalves A, Le Tri T,
Zureik M and Dray-Spira R: Risk of secondary hematologic
malignancies associated with breast cancer chemotherapy and G-CSF
support: A nationwide population-based cohort. Int J Cancer.
148:375–384. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lyman GH, Yau L, Nakov R and Krendyukov A:
Overall survival and risk of second malignancies with cancer
chemotherapy and G-CSF support. Ann Oncol. 29:1903–1910. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lustberg MB, Kuderer NM, Desai A, Bergerot
C and Lyman GH: Mitigating long-term and delayed adverse events
associated with cancer treatment: Implications for survivorship.
Nat Rev Clin Oncol. 20:527–542. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jabagi MJ, Vey N, Goncalves A, Le Tri T,
Zureik M and Dray-Spira R: Evaluation of the incidence of
hematologic malignant neoplasms among breast cancer survivors in
France. JAMA Network Open. 2:e1871472019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cowell IG and Austin CA: Mechanism of
generation of therapy related leukemia in response to
anti-topoisomerase II agents. Int J Environ Res Public Health.
9:2075–2091. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Travis LB, Holowaty EJ, Bergfeldt K, Lynch
CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala
E, et al: Risk of leukemia after platinum-based chemotherapy for
ovarian cancer. N Engl J Med. 340:351–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rosenstock AS, Niu J, Giordano SH, Zhao H,
Wolff AC and Chavez-MacGregor M: Acute myeloid leukemia and
myelodysplastic syndrome after adjuvant chemotherapy: A
population-based study among older breast cancer patients. Cancer.
124:899–906. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patel AA, Rojek AE, Drazer MW, Weiner H,
Godley LA, Le Beau MM and Larson RA: Therapy-related myeloid
neoplasms in 109 patients after radiation monotherapy. Blood Adv.
5:4140–4148. 2021.PubMed/NCBI
|
|
27
|
Kaplan H, Malmgren J and De Roos AJ: Risk
of myelodysplastic syndrome and acute myeloid leukemia post
radiation treatment for breast cancer: A population-based study.
Breast Cancer Res Treat. 137:863–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim B, Yun W, Lee ST, Choi JR, Yoo KH, Koo
HH, Jung CW and Kim SH: Prevalence and clinical implications of
germline predisposition gene mutations in patients with acute
myeloid leukemia. Sci Rep. 10:142972020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosenberg PS, Alter BP and Ebell W: Cancer
risks in Fanconi anemia: Findings from the German Fanconi Anemia
Registry. Haematologica. 93:511–517. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feurstein S, Trottier AM, Estrada-Merly N,
Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL,
Scott BL, et al: Germ line predisposition variants occur in
myelodysplastic syndrome patients of all ages. Blood.
140:2533–2548. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oldreive CE, Byrd PJ, Stewart GS, Taylor
AJ, Farhat S, Skowronska A, Smith E, Raghavan M, Janic D,
Dokmanovic L, et al: PALB2 variant status in hematological
malignancies-a potential therapeutic target? Leuk Lymphoma.
60:1823–1826. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sy SM, Huen MS and Chen J: PALB2 is an
integral component of the BRCA complex required for homologous
recombination repair. Proc Natl Acad Sci USA. 106:7155–7160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
